The Figure shows the primary results of RE-LY.[96] Dabigatran 150 bid (black line) had a statistically significantly lower probability of the composite endpoint of stroke and systemic embolism than did warfarin.  Dabigatran 110 mg bid (dark blue line) was non-inferior to warfarin (light blue line), with both of these latter two having a similar probability of endpoint events.

 Reiffel JA. Am J Med 2013; 126: 00-00.